As an indication of KEYNOTE-048, the recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC) patients with a higher combined positive score (CPS > 20) showed a favourable response to anti-PD-1 therapy [3]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.